Pediatric blood & cancer
-
Pediatric blood & cancer · Jun 2007
Clinical TrialLongitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Anthracyclines are effective antineoplastic drugs in acute myelogenous leukemia (AML). However, their use is limited by cardiomyopathy, which occurs in children already at cumulative doses of 300 mg/m(2) (given as daunorubicin equivalent). ⋯ In spite of a highly intensive and effective treatment, the frequency of anthracycline-associated cardiomyopathy was low in the AML-BFM studies.